Resiquimod and polyinosinic–polycytidylic acid formulation with aluminum hydroxide as an adjuvant for foot-and-mouth disease vaccine

Zhou, Chun-Xue; Li, Dongdong; Chen, Yingli; Lu, Zengjun; Sun, Pu; Cao, Yimei; Bao, Huang; Fu, Yuanfang; Li, Pinghua; Bai, Xingwen; Xie, Baoxia; Liu, Zaixin

doi:10.1186/1746-6148-10-2

Cited by 23 publications

(16 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous research demonstrated that Poly I:C can reduce the replication of Chikungunya virus in vitro [39] and pretreatment of mice with poly I:C provided significant protection against SARS and influenza infection [40]. Poly I:C was also effective as an adjuvant for Foot and Mouth disease vaccine in pigs [23,41] and for influenza virus vaccine studies in chickens [42,43]. In humans, efficacy and safety of Ampligen (synthetic poly I:C) are being tested in clinical experiments.…”

Section: Discussionmentioning

confidence: 99%

Poly I:C adjuvanted inactivated swine influenza vaccine induces heterologous protective immunity in pigs

Thomas

Wang

Sreenivasan

et al. 2015

Vaccine

View full text Add to dashboard Cite

Swine influenza is widely prevalent in swine herds in North America and Europe causing enormous economic losses and a public health threat. Pigs can be infected by both avian and mammalian influenza viruses and are sources of generation of reassortant influenza viruses capable of causing pandemics in humans. Current commercial vaccines provide satisfactory immunity against homologous viruses; however, protection against heterologous viruses is not adequate. In this study, we evaluated the protective efficacy of an intranasal Poly I:C adjuvanted UV inactivated bivalent swine influenza vaccine consisting of Swine/OH/24366/07 H1N1 and Swine/CO/99 H3N2, referred as PAV, in maternal antibody positive pigs against an antigenic variant and a heterologous swine influenza virus challenge. Groups of three-week-old commercial-grade pigs were immunized intranasally with PAV or a commercial vaccine (CV) twice at 2 weeks intervals. Three weeks after the second immunization, pigs were challenged with the antigenic variant Swine/MN/08 H1N1 (MN08) and the heterologous Swine/NC/10 H1N2 (NC10) influenza virus. Antibodies in serum and respiratory tract, lung lesions, virus shedding in nasal secretions and virus load in lungs were assessed. Intranasal administration of PAV induced challenge viruses specific-hemagglutination inhibition- and IgG antibodies in the serum and IgA and IgG antibodies in the respiratory tract. Importantly, intranasal administration of PAV provided protection against the antigenic variant MN08 and the heterologous NC10 swine influenza viruses as evidenced by significant reductions in lung virus load, gross lung lesions and significantly reduced shedding of challenge viruses in nasal secretions. These results indicate that Poly I:C or its homologues may be effective as vaccine adjuvants capable of generating cross-protective immunity against antigenic variants/heterologous swine influenza viruses in pigs.

show abstract

Section: Discussionmentioning

confidence: 99%

Poly I:C adjuvanted inactivated swine influenza vaccine induces heterologous protective immunity in pigs

Thomas

Wang

Sreenivasan

et al. 2015

Vaccine

View full text Add to dashboard Cite

show abstract

“…Combining adjuvants could be as beneficial as the tailoring of the response, and several publications have shown synergistic effects. Plant‐derived adjuvants, in this case rapeseed oil and ginseng saponins (Zhang et al., ), and the synthetic TLR7/8 ligand R848 and poly I:C combined with a traditional aluminium hydroxide‐adjuvanted vaccine (Zhou et al., ), have shown promise. An oil/gel combination (ISA 201, Carbigen, Emulsigen‐D) also induced improved immunity compared to traditional vaccines in pigs.…”

Section: Literature Reviewmentioning

confidence: 99%

Global Foot-and-Mouth Disease Research Update and Gap Analysis: 3 - Vaccines

Robinson

Knight-Jones

Charleston

et al. 2016

Transbound Emerg Dis

View full text Add to dashboard Cite

SummaryThis study assessed research knowledge gaps in the field of FMDV (foot-andmouth disease virus) vaccines. The study took the form of a literature review combined with research updates collected in 2014 from 33 institutes from across the world. Findings were used to identify priority areas for future FMD vaccine research. Vaccines play a vital role in FMD control, used both to limit the spread of the virus during epidemics in FMD-free countries and as the mainstay of disease management in endemic regions, particularly where sanitary controls are difficult to apply. Improvements in the performance or cost-effectiveness of FMD vaccines will allow more widespread and efficient disease control. FMD vaccines have changed little in recent decades, typically produced by inactivation of whole virus, the quantity and stability of the intact viral capsids in the final preparation being key for immunogenicity. However, these are exciting times and several promising novel FMD vaccine candidates have recently been developed. This includes the first FMD vaccine licensed for manufacture and use in the USA; this adenovirus-vectored FMD vaccine causes in vivo expression of viral capsids in vaccinated animals. Another promising vaccine candidate comprises stabilized empty FMDV capsids produced in vitro in a baculovirus expression system. Recombinant technologies are also being developed to improve otherwise conventionally produced inactivated vaccines, for example, by creating a chimeric vaccine virus to increase capsid stability and by inserting sequences into the vaccine virus for desired antigen expression. Other important areas of ongoing research include enhanced adjuvants, vaccine quality control procedures and predicting vaccine protection from immune correlates, thus reducing dependency on animal challenge studies. Globally, the degree of independent vaccine evaluation is highly variable, and this is essential for vaccine quality. Previously neglected, the importance of evaluating vaccination programme effectiveness and impact is increasingly being recognized.

show abstract

“…Zhou et al . (2014) reported that mice immunized with TLR7 ligands showed a markedly enhanced resistance to FMDV 30 . Kato et al .…”

Section: Discussionmentioning

confidence: 99%

Tongue Epithelium Cells from shRNA Mediated Transgenic Goat Show High Resistance to Foot and Mouth Disease Virus

Wang

Kang

et al. 2015

Sci Rep

View full text Add to dashboard Cite

Foot and mouth disease induced by foot and mouth disease virus (FMDV) is severe threat to cloven-hoofed domestic animals. The gene 3Dpol in FMDV genome encodes the viral RNA polymerase, a vital element for FMDV replication. In this study, a conserved 3D-7414shRNA targeting FMDV-3Dpol gene was designed and injected into pronuclear embryos to produce the transgenic goats. Sixty-one goats were produced, of which, seven goats positively integrated 3D-7414shRNA. Loss of function assay demonstrated that siRNA effectively knockdown 3Dpol gene in skin epithelium cells of transgenic goats. Subsequently, the tongue epithelium cells from transgenic and non-transgenic goats were infected with FMDV O/YS/CHA/05 strain. A significant decrease of virus titres and virus copy number was observed in cells of transgenic goats compared with that of non-transgenic goats, which indicated that 3D-7414siRNA inhibited FMDV replication by interfering FMDV-3Dpol gene. Furthermore, we found that expression of TLR7, RIG-I and TRAF6 was lower in FMDV infected cells from transgenic goats compared to that from non-transgenic goats, which might result from lower virus copy number in transgenic goats’ cells. In conclusion, we successfully produced transgenic goats highly expressing 3D-7414siRNA targeting 3Dpol gene, and the tongue epithelium cells from the transgenic goats showed effective resistance to FMDV.

show abstract

Resiquimod and polyinosinic–polycytidylic acid formulation with aluminum hydroxide as an adjuvant for foot-and-mouth disease vaccine

Cited by 23 publications

References 26 publications

Poly I:C adjuvanted inactivated swine influenza vaccine induces heterologous protective immunity in pigs

Poly I:C adjuvanted inactivated swine influenza vaccine induces heterologous protective immunity in pigs

Global Foot-and-Mouth Disease Research Update and Gap Analysis: 3 - Vaccines

Tongue Epithelium Cells from shRNA Mediated Transgenic Goat Show High Resistance to Foot and Mouth Disease Virus

Contact Info

Product

Resources

About